OLD Mission Capital LLC Purchases New Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

OLD Mission Capital LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,868 shares of the company's stock, valued at approximately $293,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. US Bancorp DE raised its stake in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock worth $362,000 after buying an additional 121 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in shares of Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after acquiring an additional 123 shares during the period. Xponance Inc. lifted its stake in shares of Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company's stock worth $280,000 after acquiring an additional 155 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock valued at $762,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $220.00.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Trading Up 2.7 %

Krystal Biotech stock traded up $4.35 during mid-day trading on Friday, hitting $165.00. 426,700 shares of the company's stock were exchanged, compared to its average volume of 295,707. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The stock has a 50 day moving average of $173.96 and a two-hundred day moving average of $172.25. The stock has a market cap of $4.75 billion, a P/E ratio of 55.18 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the firm posted $0.30 EPS. The firm's revenue for the quarter was up 116.4% on a year-over-year basis. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).